166 related articles for article (PubMed ID: 32209458)
1. Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design.
Leighow SM; Liu C; Inam H; Zhao B; Pritchard JR
Cell Rep; 2020 Mar; 30(12):3951-3963.e4. PubMed ID: 32209458
[TBL] [Abstract][Full Text] [Related]
2. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
3. Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Kamasani S; Akula S; Sivan SK; Manga V; Duyster J; Vudem DR; Kancha RK
Tumour Biol; 2017 May; 39(5):1010428317701643. PubMed ID: 28475010
[TBL] [Abstract][Full Text] [Related]
4. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
5. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
7. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
8. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
9. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Sacha T; Hochhaus A; Hanfstein B; Müller MC; Rudzki Z; Czopek J; Wolska-Smoleń T; Czekalska S; Salamanchuk Z; Jakóbczyk M; Skotnicki AB
Leuk Res; 2003 Dec; 27(12):1163-6. PubMed ID: 12921956
[TBL] [Abstract][Full Text] [Related]
10. Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
Balasubramanian P; Chopra A; Verma D; Singh IK; Kumar A; Sharma A; Kumar R
Leuk Lymphoma; 2017 Jul; 58(7):1750-1752. PubMed ID: 27868464
[No Abstract] [Full Text] [Related]
11. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.
Lu T; Chen C; Wang A; Jiang Z; Qi Z; Hu Z; Hu C; Liu F; Wang W; Wu H; Wang B; Wang L; Qi S; Wu J; Wang W; Tang J; Yan H; Bai M; Liu Q; Liu J
Cancer Lett; 2019 Apr; 447():105-114. PubMed ID: 30684595
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
[TBL] [Abstract][Full Text] [Related]
13. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Takahashi T; Elzawahry A; Mimaki S; Furukawa E; Nakatsuka R; Nakamura H; Nishigaki T; Serada S; Naka T; Hirota S; Shibata T; Tsuchihara K; Nishida T; Kato M
Genes Chromosomes Cancer; 2017 Apr; 56(4):303-313. PubMed ID: 27997714
[TBL] [Abstract][Full Text] [Related]
14. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
15. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
16. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
[TBL] [Abstract][Full Text] [Related]
17. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
18. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance.
Yin Z; Huang G; Gu C; Liu Y; Yang J; Fei J
Clin Cancer Res; 2020 Aug; 26(15):4040-4053. PubMed ID: 32098768
[TBL] [Abstract][Full Text] [Related]
20. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
